Transcript Prezentacja programu PowerPoint

INTRODUCTION TO
POLPHARMA BIOLOGICS
BIO USA
Washington DC, June 27, 2011
Piotr Lassota, Ph.D.
2015-07-17
1
POLPHARMA in SHORT
• 75 Years old (founded in 1935 in Starogard Gdanski)
• Privately owned (re-privatized in 2000)
 One owner: Mr. Jerzy Starak
•
•
•
•
•
Focused on small molecule generics
Approx. 4,550 employees
Experienced, international Management Team
Traditionally Strong R&D (300 FTEs)
Dominant position in Poland, 50% Revenue from Export
 Subsidiaries/strategic partners in Spain, Russia and Turkey
• Highly Profitable
7/17/2015
2
POLPHARMA NOW
Integrated
Pharma
Group
Strategic Alliances
Total Employment of ca.
Commercial
operations
Poland
Trade Office
in Warsaw
Manufacturing
Operations
Starogard
API and FDF
production
R&D (both APIs
and FDFs)
4550 persons
Manufacturing
Operations
Sieradz
Representative
Offices
S&M organisations
FDF production and in Baltic countries,
R&D
Hungary, Ukraina &
(special forms)
Moldovia, CIS countries
Anti-infectives
FDF ‘s at
Duchnice
FDF production
of oral cephalosporins and sterile
powder injections
Russian
operations
Akrikhin
Farmaprojects
Cenova
Pharma
S&M organisation FDF Products
production
development
R&D unit
organization
Turkey S&M
organisations
Ca. 1143 people
Ca. 118 people
and Vietnam
Ca. 110 people
Ca. 1074 people
Ca. 1516 people
2015-07-17
Ca. 296 people
Ca. 190 people
Ca. 103 people
3
POLPHARMA MANAGEMENT
Position
CEO
Name
Jacek Glinka
Years of experience
pharma/executive
8 /23
Previous companies
Delloitte & Touche /A.T.
Kearney
COO
CFO
Commercial Director
R&D Director &
Portfolio Director
International Market
Commercial Director
Theodore Iliopoulos
Włodzimierz Gryglewicz
Rajmund Martyniuk
Brina Ornik
Christian Freund
37 /17
8/18
16 /11
16 /12
21/19
Bristol Myers Squibb/
Patheon
Coca-Cola/ Schöller/ Brok
Brewery
SmithKline Beecham/
Pfizer/ Astra
Lek/ Sandoz Group
MSD/Ökopharm/ BASF/
EBEWE/ BMS
Pharma BU Director
Scientific Director
Biotech BU
Global Strategic Sourcing
Director
Director Biotech
Tomasz Moys
Piotr Lassota
Bożenna Kozakiewicz
Klaus Martin
21 /18
23/14
10/20
8/8
Polfa Starogard
American Cyanamid/
Wyeth/ Novartis/ Caliper
Life Science
Foreign Trade Office,
private company working
with Polish pharma
companies
Sandoz / Sandoz
Biopharmaceuticals
2015-07-17
4
POLPHARMA IN POLAND
Market share by volume in 2010
-
2%
4%
6%
8%
10%
12%
14%
Market share by value in 2010
16%
18%
-
Sandoz Corp.
Sandoz Corp.
Teva Group
Teva Group
Valeant Pharma
Krka
Krka
Adamed
Gedeon Richter Cor
Zentiva
Tarchomin Zf Plf
Gedeon Richter Cor
Warszawa Zf Plf
Zentiva
Sanitas Lithuania
Adamed
Servier
Polfarmex
Menarini
Biofarm
Pabianice Zf Plf
Apotex
Actavis
Lek-Am
I.B.A. Bioton
2%
4%
6%
8%
10%
12%
14%
Servier
Valeant Pharma
Biofarm
Warszawa Zf Plf
Tarchomin Zf Plf
Sanitas Lithuania
Lek-Am
Menarini
Polfarmex
Apotex
Pabianice Zf Plf
Actavis
I.B.A. Bioton
2015-07-17
5
POLPHARMA: OUR JOURNEY
2015-07-17
6
POLPHARMA: STRONG R&D
6 000 000
5 000 000
4 000 000
3 000 000
MAXIGRA
VIAGRA
2 000 000
1 000 000
0
Maxigra (sildenafil) – launched March 2007,
performance in first 2 years
2015-07-17
7
POLPHARMA: OUR JOURNEY
2015-07-17
8
POLPHARMA: ENTERING
BIOLOGICS
Polpharma aims to enter biologics and started to build a platform for biotech market
2010
2011
2012
2013
2014
2015
2016
Entering the Biosimilar market
2017
2018
Co-marketing i in-licensing
 Protein
Protein
 Monoclonal antibody
Antibody
 Antibody and/or Protein
Biotech
partner 1
Antibody and/or protein
WE
Co-development
partner
Antibody
Biotech
partner 2
PPH
Bioplatform
Monoclonal antibody
Protein Family
 Monoclonal
In-houseantibody
development

Monoclonal
antibody
Monoclonal antibody
Global
Partner
US
partner
Monoclonal antibody
starting R&D researches
Own development
Oncology antibody-based Therapy
Oncology Non-peptide-based Therapy
Non-Oncology Biologic Therapy
2015-07-17
9
POLPHARMA BIOLOGICS
ULTRA MODERN R&D SITE
• Location: Gdańsk Science and Technology Park
• Approx. 25,000 sq.ft.
 Initially 45 FTEs
 Analytical
R&D Laboratories
 Process Development
 Purification
 Formulation
 Pilot Plant (500L SUS)
• Leased on 12/14/2010
 Conceptual & Engineering Designs completed
 Work starts next Month
 Occupancy: Q1 2012
2015-07-17
10
POLPHARMA BIOLOGICS
COOPEARTION WITH GSTP
2015-07-17
11
POLPHARMA BIOLOGICS
COOPEARTION WITH GPN-T
RECENT GSTP EXPANSION
The third phase of the Park expansion
is scheduled to complete by Q1 2012.
The new modern office and lab space
will house many biotechs. The
research and development institutes
and centers situated here will turn
Gdansk into a hub of innovation.
The benefits of the Gdansk Science
and Technology Park have been
recognized by many institutions,
including Polpharma. Our company
is in the process of constructing
modern R&D laboratories in the GSTP.
For more information please contact us at:
[email protected]
or, visit our Website:
www.polpharmabiologics.com
Thank you for your attention!
2015-07-17
13